Hernia Repair: No Simple Solution
Executive Summary
Hernia repair is a staple of the general surgeon’s practice, with more than two million procedures performed annually worldwide. However, the procedure has proven problematic due to the mesh products used to repair the hernia defect and their potential to cause complications over time. At the Fifth International Hernia Congress, held recently in New York City, physicians debated the pros and cons of the many hernia repair mesh products that are now available. Although the general consensus at the meeting was there is no “ideal mesh,” mesh manufacturers continue to innovate in this field, offering a host of new products for this $500+ million market, including a variety of biologic meshes for complex repairs, synthetic meshes with biologic-like properties, fully resorbable meshes, and meshes with bacteriostatic properties.
You may also be interested in...
Acellular Dermal Matrices: The New Standard In Breast Reconstruction
Recent advances in breast cancer surgical techniques, such as the advent of nipple-sparing mastectomy, along with growing physician acceptance of new biomaterials capable of improving outcomes following implant-based breast reconstruction, are making mastectomy and reconstruction surgery a more attractive treatment option for many breast cancer patients and will help drive strong growth in the US breast reconstruction market in the years ahead.
MIS: Challenges in an Evolving Market
Technology and techniques for minimally invasive surgery continue to evolve as medical device manufacturers and clinicians alike look for ways to further minimize the invasiveness, pain, and scarring associated with surgery. At the same time, the economy and health care reform have created challenges for medical device manufacturers. In response to these challenges, mannufacturers competing in the MIS market are developing new products and marketing strategies designed to ease both the economic and environmental impact for providers.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.